Výsledky vyhledávání - "Jose Antonio Karam"

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010):a multicentre, randomised, double-blind, phase 3 trial

Publikováno v: Pal, S K, Uzzo, R, Karam, J A, Master, V A, Donskov, F, Suarez, C, Albiges, L, Rini, B, Tomita, Y, Kann, A G, Procopio, G, Massari, F, Zibelman, M, Antonyan, I, Huseni, M, Basu, D, Ci, B, Leung, W, Khan, O, Dubey, S & Bex, A 2022, ' Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010) : a multicentre, randomised, double-blind, phase 3 trial ', The Lancet, vol. 400, no. 10358, pp. 1103-1116 . https://doi.org/10.1016/S0140-6736(22)01658-0

Background: The standard of care for locoregional renal cell carcinoma is surgery, but many patients experience recurrence. The objective of the current study was to determine if adjuvant atezolizumab (vs placebo) delayed recurrence in patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41788364e9f8cf4a98f933a9cb5b02a7
https://pure.au.dk/portal/da/publications/adjuvant-atezolizumab-versus-placebo-for-patients-with-renal-cell-carcinoma-at-increased-risk-of-recurrence-following-resection-immotion010(03983b59-e7e4-481c-a4db-270548485b3b).html

Zobrazit plný text záznamu

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Thomas Powles, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Thomas Ferguson, Stefan N Symeonides, Jaroslav Hajek, Howard Gurney, Yen-Hwa Chang, Jae Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B Haas, Piotr Sawrycki, Joseph E Burgents, Lei Xu, Kentaro Imai, David I Quinn, Toni K Choueiri, Toni Choueiri, Thomas R. Ferguson, Tzu-Ping Lin, Stefan N. Symeonides, Naomi B. Haas, Howard P. Gurney, Christine Chevreau, John M. Burke, Gurjyot Doshi, Bohuslav Melichar, Delphine Topart, Stephane Oudard, Evgeniy Kopyltsov, Hans-Joerg Hammers, David I. Quinn, Ajjai Alva, Juliana de Janoski Menezes, Adriano Goncalves e Silva, Eric W. Winquist, Alketa Hamzaj, Giuseppe Procopio, Boguslawa Karaszewska, Ewa M. Nowakowska-Zajdel, Boris Y. Alekseev, Rustem A. Gafanov, Adel Izmailov, Andrey Semenov, Sergey G. Afanasyev, Oleg N. Lipatov, Thomas B. Powles, Sandy Srinivas, David McDermott, Samith T. Kochuparambil, Ian D. Davis, Katriina Peltola, Roberto Sabbatini, Jinsoo Chung, Michail I. Shkolnik, Vsevolod B. Matveev, Pablo Gajate Borau, Steven McCune, Thomas E. Hutson, Alejandro Dri, Silvio Correia Sales, Carrie Yeung, Carmen Marcela Alcala Castro, Peter Bostrom, Brigitte Laguerre, Consuelo Buttigliero, Ugo de Giorgi, Eugeniy A. Fomin, Yousef Zakharia, Clara Hwang, Eric A. Singer, Jeffrey T. Yorio, David Waterhouse, Ruben Dario Kowalyszyn, Margarita Sonia Alfie, Eduardo Yanez Ruiz, Tomas Buchler, Krista Kankaanranta, Gianluigi Ferretti, Go Kimura, Kazuo Nishimura, Naoya Masumori, Satoshi Tamada, Haruaki Kato, Hiroshi Kitamura, Iwona Danielewicz, Joanna Wojcik-Tomaszewska, Nuria Sala Gonzalez, Kun-Yuan Chiu, Michael B. Atkins, Elisabeth Heath, Gustavo Adolfo Rojas-Uribe, Manuel Enrique Gonzalez Fernandez, Susan Feyerabend, Sandro Pignata, Kazuyuki Numakura, Bozena Cybulska Stopa, Ruslan Zukov, Miguel Angel Climent Duran, Pablo Jose Maroto Rey, Alvaro Montesa Pino, Chao-Hsiang Chang, Salil Vengalil, Tom S. Waddell, Patrick W. Cobb, Ralph Hauke, Daniel M. Anderson, John Sarantopoulos, Theodore Gourdin, Tian Zhang, Gautam Jayram, Luis Enrique Fein, Carole Harris, Patricia Medeiros Milhomem Beato, Francisco Flores, Angela Estay, Juan Andres Rubiano, Jens Bedke, Stefan Hauser, Andreas Neisius, Jonas Busch, Satoshi Anai, Hiroyuki Tsunemori, Dariusz Sawka, Bozena Sikora-Kupis, Jose Angel Arranz, Ignacio Delgado, Chung-Hsin Chen, Elizabeth Gunderson, Scott Tykodi, Alan Koletsky, Kevin Chen, Manish Agrawal, Diego Lucas Kaen, Juan Pablo Sade, Marcelo Daniel Tatangelo, Francis Parnis, Fernando Maciel Barbosa, Genevieve Faucher, Nayyer Iqbal, Daniele Marceau, Jean-Benoit Paradis, Nawar Hanna, Alejandro Acevedo, Carolina Ibanez, Luis Villanueva, Pedro Pablo Galaz, Isabel Cristina Durango, Ray Manneh, Zdenek - Kral, Petra Holeckova, Heikki Hakkarainen, Hanna Ronkainen, Sophie Abadie-Lacourtoisie, Sophie Tartas, Peter J. Goebell, Marc-Oliver Grimm, Thomas Hoefner, Manfred Wirth, Andrej Panic, Wolfgang Schultze-Seemann, Akira Yokomizo, Ryuichi Mizuno, Hirotsugu Uemura, Masatoshi Eto, Masao Tsujihata, Yoshihisa Matsukawa, Yoji Murakami, Miso Kim, Paul Hamberg, Malgorzata Marczewska-Skrodzka, Cezary Szczylik, Alison C. Humphreys, Peter Jiang, Birendra Kumar, Gary Lu, Arpita Desai, Jose Antonio Karam, George Keogh, Mark Fleming, Juan Jose Zarba, Viviana E. Leiva, Guillermo Ariel Mendez, Samuel J. Harris, Stephen J. Brown, Joao Neif Antonio Junior, Rita de Cassia Costamilan, Roberto Odebrecht Rocha, David Muniz, Leandro Brust, Aly-Khan Lalani, Jeffrey Graham, Michael Levesque, Francisco Orlandi, Rostislav Kotasek, Jean L. Deville, Delphine Borchiellini, Axel Merseburger, Michael Rink, Frederik Roos, Ray McDermott, Masafumi Oyama, Yoshiaki Yamamoto, Yoshihiko Tomita, Yuji Miura, Naomasa Ioritani, Hans Westgeest, Tomasz Kubiatowski, Wieslaw Bal, Regina Girones Sarrio, Julie Rowe, Debra M. Prow, Francis Senecal, Neda Hashemi-Sadraei, Scott W. Cole, Stephan D. Kendall, Donald A. Richards, Ian D. Schnadig, Mukul Gupta

Publikováno v: 2022, ' Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet Oncology, vol. 23, no. 9, pp. 1133-1144 . https://doi.org/10.1016/S1470-2045(22)00487-9

Background: The first interim analysis of the KEYNOTE-564 study showed improved disease-free survival with adjuvant pembrolizumab compared with placebo after surgery in patients with clear cell renal cell carcinoma at an increased risk of recurrence.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25f8e8bb143ec0a3a46038772a01c57f
https://pubmed.ncbi.nlm.nih.gov/36603923

Zobrazit plný text záznamu

Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline

Autor: Phillip M Pierorazio, Joel Sheinfeld, Stanley L. Liauw, Timothy A. Masterson, Andrew James Stephenson, Timothy Gilligan, Darren Feldman, Bradley C. Leibovich, Ritu Sharma, Eric B Bass, Joshua J. Meeks, Siamak Daneshmand, Jose Antonio Karam, David Chelnick, Scott E. Eggener

Publikováno v: Journal of Urology. 202:272-281

Testis cancer is the most common solid malignancy in young males. The purpose of this guideline is to provide a useful reference on the effective evidence-based treatment of early stage testicular cancer.The systematic review utilized to inform this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a424134c039bb985e6634f8263d63f4
https://doi.org/10.1097/ju.0000000000000318

Zobrazit plný text záznamu

Patient perspective on serving on the steering committee of the AURORAX-0087A trial for non-metastatic clear cell renal cell carcinoma

Publikováno v: Giles, R, Nair, R, Azawi, N H, Barber, N, Bex, A, Campi, R, Capitanio, U, Gatto, F, Hakimi, A A, Jarvinen, P, Karam, J, Ljungberg, B, Lund, L, Maddineni, S B, Marconi, L, Master, V, Minervini, A, Nielsen, T K, Nisen, H, Rochester, M, Stewart, G & Dabestani, S 2021, ' Patient perspective on serving on the steering committee of the AURORAX-0087A trial for non-metastatic clear cell renal cell carcinoma ', European Urology, vol. 79, no. Suppl. 1, pp. S286-S287 . https://doi.org/10.1016/S0302-2838(21)00589-3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1355cd42e7d2863343f47e7c853eb31
https://doi.org/10.1016/s0302-2838(21)00589-3

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání